Prevention of bone mineral loss by zoledronic acid in men with prostate carcinoma receiving androgen deprivation therapy: A prospective randomized trial in an indian population

Current Urology

Volumn 2, Issue 2, 2008, Pages 79-86

  Rao, M P ^a   Kumar, Abhay ^a   Goyal, Neeraj K ^a   Trivedi, Sameer ^a   Dwivedi, Udai S ^a   Singh, Pratap B ^a  

^a BANARAS HINDU UNIVERSITY   (India)

Author keywords

Androgen deprivation; Bone mineral density; Osteoporosis; Prostate cancer

Indexed keywords

CALCIUM; DEOXYPYRIDINOLINE; GONADORELIN AGONIST; PLACEBO; VITAMIN D; ZOLEDRONIC ACID;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANDROGEN DEPRIVATION THERAPY; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BONE DENSITY; BONE MINERAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FLU LIKE SYNDROME; HUMAN; INDIA; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; OSTEOLYSIS; PRIORITY JOURNAL; PROSTATE CARCINOMA; SIDE EFFECT; SOMNOLENCE; THROMBOPHLEBITIS;

EID: 77953392961     PISSN: 16617649     EISSN: 16617657     Source Type: Journal    
DOI: 10.1159/000115412     Document Type: Article

References (24)

1. Reiter RE, dcKemion JB: Epidemiology, etiology and prevention of prostate cancer; in: Walsh PC, Retik AB, Vaughan ED, Wein J, Kavoussi LR, Novick AC, Partin AW, Peters CA (eds): Campbell's Urology. ed 8, Philadelphia, Saunders, 2002, pp3003-3024.
2. Ross R, Bernstein L, Judd H, Hanisch R, Pike M, Henderson B: Serum testosterone levels in healthy young black and white men. J Natl Cancer Inst 1986;76:45-8.
3. Bruder DM, Welch MD: Prevalence of os-teopenia and osteoporosis by central and peripheral bone mineral density in men with prostate cancer during androgen deprivation (abstract). J Bone Miner Res 2002;17:411.
4. Oefelein MG, Ricchuiti V, Conrad W, Seftel A, Bodner D, Goldman H, Resnick M: Skeletal fracture associated with androgen suppression induced osteoporosis: The clinical incidence and risk factors for patients with prostate cancer. J Urol 2001;166:1724-1728.
5. Modi S, Wood L, Siminoski K: A comparison of prevalence of osteoporosis and vertebral fractures in men with prostate cancer on various androgen deprivation therapies: preliminary report (abstract). Proc Am Soc Clin Oncol 2001;20(suppl B):167.
6. Melton LJ 3rd, Alothman Kl, Khosla S, Achenbach SJ, Oberg AL, Zincke H: Fracture risk following bilateral orchiectomy. J Urol 2003;169:1747-50.
7. Diamond T, Campbell J, Bryant C, Lynen W: The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostatic carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy. Cancer 1998; 83:1561-1566.
8. Luisetto G, Bottega F, Zangari M, Tizian L, Scalella P, Pozzuoli A: Effects of three therapeutic regimens on postmenopausal bone loss in oophorectomized women. Curr Ther Res 1996;57:839-848.
9. Diamond TH, Higano CS, Smith MR, Guise TA, Singer FR: Osteoporosis in men with prostate carcinoma receiving androgen-depri-vation therapy: recommendations for diagnosis and therapies. Cancer 2004;100:892-899.
10. Green JR: Zoledronic acid: pharmacologic profile of a potent bisphosphonate. J Organo-metal Chem. 2005;690:2439-2448.
11. Tanvetyanon T: Physician practices of bone density testing and drug prescribing to prevent or treat osteoporosis during androgen deprivation therapy. Cancer 2005;103:237-241.
12. Alibhai SM, Rahman S, Warde PR, Jewett MA, Jaffer T, Cheung AM: Prevention and management of osteoporosis in men receiving androgen deprivation therapy: a survey of urologists and radiation oncologists. Urology 2006;68:126-131.
13. Saad F, Gleason DM, Murray R, Tchekm-edyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Chen B; Zoledronic Acid Prostate Cancer Study Group: A randomized, placebo-controlled trial of zole-dronic acid in patients with hormone-refractory metastatic prostate cancer. J Natl Cancer Inst 2002;94:1458-1468.
14. Diamond TH, Winters J, Smith A, De Souza P, Kersley JH, Lynch WJ, Bryant C: The anti-osteoporotic efficacy of intravenous pamidro-nate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study. Cancer 2001;92:1444-1450.
15. Smith MR, McGovern FJ, Zietman AL, Fal-lon MA, Hayden DL, Schoenfeld DA, Kant-off PW, Finkelstein JS: Pamidronate to prevent bone lose during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001;345:948-955.
16. Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N: Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostatic cancer. J Urol 2003;169:2008-2012.
17. Green JR, Muller K, Jaeggi KA: Preclinical pharmacology of CGP 42'446, a new potent, heterocyclic biphosphonate compound.J.
18. Bone Miner Res 1994;9:745-751.Ryan CW, Huo D, Demers LM, Beer TM, Lacerna LV: Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer. J Urol 2006;176:972-978.
19. Michaelson MD, Kaufman DS, Lee H, Mc-Govern FJ, Kantoff PW, Fallon MA, Finkel-stein JS, Smith MR: Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol 2007;25:1038-1042.
20. Wei JT, Gross M, Jaffe CA, Gravlin K, La-haie M, Faerber GJ, Cooney KA: Androgen deprivation therapy for prostate cance results in significant loss of bone density. Urology 1999;54:607-611.
21. Smith MR, McGovern FJ, Fallon MA, Schoenfeld D, Kantoff PW, Finkelstein JS: Low bone mindral density in hormone-naive men with prostate carcinome. Cancer 2001; 91:2238-2245.
22. Orwoll E: Assessing bone density in men. J Bone Miner Res 2000;15:1867-1870.
23. Higano CS: Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician. Urol Clin North Am 2004;31:331-352.
24. Reid lR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U, Widmer A, De-vogelaer JP, Kaufman JM, Jaeger P, Body JJ, Brandi ML, Broell J, Di Micco R, Genazzani AR, Felsenberg D, Happ J, Hooper MJ, lttner J, Leb G, Mallmin H, Murray T, Ortolani S, Rubinacci A, Saaf M, Samsioe G, Verbrug-gen L, Meunier PJ: lntravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002;346:653-661